▎Edited by the WuXi AppTec content team
According to incomplete statistics from Innovation Radar, last week (February 19 to February 25), the global health sectorA total of 27 financing events were disclosed, with a total amount exceeding 5 billion yuan.. In terms of the amount, there were 11 financings of 100 million yuan and above.According to the disclosed financing rounds, there were 16 early-stage financings (before Series B) and 9 mid-to-late stage financings (Series B and onwards).Start.Six companies in the biopharmaceutical field have received financing, involving drug types including antibody-drug conjugates, peptides, vaccines, targeted therapies, and more.
#01
Evopoint Biosciences Completes $700 Million Series E Financing
Keywords: Targeted therapy, Antibody-drug conjugatesLatest Financing:RMB 700 Million Series EThis round of investment institutions: Chenhai Capital, Guoxin Investment, Pudong Venture Capital, Tencent Investment, Zhenxin Valley Innovation Capital, etc.On February 20, Evopoint Biosciences announced the successful completion of a Series E financing round worth 700 million yuan.The proceeds from this round of financing will be mainly used to advance the company’s multiple clinical trials, and further enhance its three self-innovated technology platforms: targeted therapy, anti-infectives, and protein degradation targeted chimera., accelerating the operation of production bases and the construction of commercialization teams to promote the early market entry of products for the benefit of a wide range of patients. Evopoint Biosciences was founded in 2017 and is committed to providing high-quality solutions for significant unmet clinical needs worldwide. Based on its self-innovative technology platforms, Evopoint Biosciences has developed a pipeline of innovative drugs, including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation antibody-drug conjugates (ADCs), covering disease areas such as cancer, multidrug-resistant bacterial infections, and metabolic disorders. Currently, the company has nine products in clinical development, two of which have entered Phase 3 clinical trials.
#02
Frontier Medicines Completes $80 Million Series C Financing
Keywords：Difficult-to-Drug Target DrugsLatest Financing:$80 Million Series CThis round of investment institutions: Deerfield Management, Droia Ventures, Galapagos, MPM Capital, RA Capital Management, etc.On February 22, Frontier Medicines announced the completion of an $80 million Series C financing round. This Series C financing willFor the clinical development of its potential "first-in-class" KRAS G12C inhibitor FMC-376 and other pipeline products。Frontier Medicines is a clinical-stage precision medicine company dedicated to developing breakthrough drugs in the fields of oncology and immunology. The company has built the Frontier technology platform, which is based on covalent chemistry and machine learning for drug development. The company's lead candidate drugsFMC-376 is an investigational oral small-molecule inhibitor of KRAS G12C that can simultaneously target KRAS proteins in both active (ON) and inactive (OFF) states. This therapy has demonstrated in vivo efficacy in various models of KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, as well as in NSCLC brain metastasis models, with the potential to enhance clinical efficacy and prolong the onset of resistance.
#03
Insamo Completes $12 Million Seed Financing Round
Keywords：AI Drugs, PeptidesLatest Financing:$12 Million Seed RoundThis round of investment institutions: Axial, BEVC, Civilization Ventures, MRL Ventures Fund, Playground Global, Sahsen Ventures, etc.On February 21, Insamo announced the completion of a $12 million seed funding round.It is reported that the funds from this round of financing will be used for further development of the company's core projects.Based on artificial intelligence (AI) technology, Insamo is committed to developing permeable and orally administrable cyclic peptides.By integrating machine learning-driven molecular design, ultra-high-throughput molecular biology, and parallel synthetic chemistry, the company's proprietary platform under development can rapidly identify preclinical candidates with favorable pharmacological properties, advancing the field of drug discovery. The company’s current focus is on developing orally available cyclic peptide formulations to replace injectable or intravenous biologics, while also aiding in drug discovery for currently challenging drug targets to improve patient outcomes.
#04
Kun Qin Biotech Completes Financing of Tens of Millions of Yuan
Latest Financing:Tens of Millions of Yuan UnknownRoundThis Round's Investment Institution: Shaanxi Venture CapitalOn February 21, Kunqin Biotech successfully completed a financing round worth tens of millions of yuan. The funds obtained will be used for the company's R&D investment, production line operations, and market layout, among others. Kunqin Biotech is aFocus on the development and translation of recombinant protein drugs, and human vaccine research and development., a biopharmaceutical company engaged in the production and sales. Public information shows that since its establishment, Kunqin Biotech has been focusing on the upgrading of traditional vaccines and the research and development of innovative vaccines, actively expanding its product pipeline. It has successively developed quadrivalent influenza virus split vaccine, human diploid cell rabies vaccine, recombinant shingles vaccine, universal flu vaccine, and recombinant HPV vaccine, etc. At the same time, it leverages its technological advantages to explore and develop mRNA vaccines, new adjuvant vaccines, and novel formulation vaccines. The product pipeline mainly covers major disease areas such as cancer treatment, cardiovascular and cerebrovascular disease treatment, wound repair, and medical aesthetics.
#05
Biyang PharmaceuticalsCompleted Pre-A+ Round Financing Worth Tens of Millions of Yuan
Keywords: Targeted TherapyLatest Financing:Tens of Millions of Yuan in Pre-A+ RoundThis round of investment institutions:Yuanjin VenturesNews on February 19: Beyond Therapeutics, a rising company in innovative drug development, has recently secured tens of millions of RMB in Pre-A+ round financing.Accelerate the advancement of its R&D pipeline in ophthalmology and oncology for IND registration and application studies in China and the United States.Biyang Pharmaceuticals was founded in April 2021 and is headquartered in the Biomedical Industry Park of Suzhou Industrial Park. The company's ExCEED technology platform integrates computational modeling with wet-lab techniques to enhance early-stage drug discovery capabilities across three core areas: molecular design, drug-likeness optimization, and biological evaluation. This enables the continuous incubation of projects with "best-in-class" potential. Ophthalmology and oncology are key focus areas for Biyang Pharmaceuticals. Public information indicates that Biyang Pharmaceuticals has independently developed multiple project pipelines, including BT01001 and BT01002, which are currently undergoing IND registration studies in both China and the United States.
Readers, please star ⭐Chuangjianhui to receive updates第一时间.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress of global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media circles, but unauthorized republication or reproduction in any form by media or institutions to other platforms is strictly prohibited. For authorization to republish, please contact:"InnoView"Contact us via the WeChat Official Account.
More Data Content RecommendationsClick "InSee", Sharing Chuangjian Hui Health New Trends
